Thyroid Function in Children and Adolescents With Idiopathic Growth Hormone (GH) Deficiency After Initiation of Therapy With Recombinant GH.

IF 4.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2026-09-11 DOI:10.1016/j.eprac.2026.08.025

Aristeidis Giannakopoulos, Maria Tsanti, Ioannis Amplianitis, Alexandra Efthymiadou, Dionisios Chrysis

{"title":"Thyroid Function in Children and Adolescents With Idiopathic Growth Hormone (GH) Deficiency After Initiation of Therapy With Recombinant GH.","authors":"Aristeidis Giannakopoulos, Maria Tsanti, Ioannis Amplianitis, Alexandra Efthymiadou, Dionisios Chrysis","doi":"10.1016/j.eprac.2026.08.025","DOIUrl":null,"url":null,"abstract":"Objective: Growth hormone (GH)/insulin-like growth factor 1 (IGF-1) and thyroid axes are interconnected. Previous studies reported mixed findings regarding the effect of recombinant GH (rGH) therapy on thyroid function in children with GH deficiency (GHD). This study aimed to investigate longitudinal thyroid function changes over the first year of rGH therapy and assess the secretory capacity of the thyroid gland, using the Structure Parameter Inference Approach (SPINA-GT).Methods: Prospective longitudinal cohort study in a single tertiary center.Results: A total of 111 children with idiopathic GHD were treated with rGH (0.22 mg/kg/wk). Baseline median age was 10.0 years, with 84% being prepubertal. After 12 months of rGH therapy, IGF-1 levels significantly increased (P < .001), whereas free T4 (FT4) levels modestly declined (P = .008). Thyroid-stimulating hormone (TSH) and SPINA-GT index did not show significant changes. Mixed-effects modeling analysis revealed association of FT4 with IGF-1 SD score (P < .001), whereas TSH was not associated with any covariate.Conclusion: The findings of our study are consistent with most previous studies, confirming that rGH therapy in children with GHD induces a modest, statistically significant decline in FT4 while maintaining stable TSH. FT4 was associated with the increase of IGF-1 SD score during rGH therapy while the addition of SPINA-GT evaluation supports the preservation of the thyroid secretory reserve during the first year of rGH treatment.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eprac.2026.08.025","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Growth hormone (GH)/insulin-like growth factor 1 (IGF-1) and thyroid axes are interconnected. Previous studies reported mixed findings regarding the effect of recombinant GH (rGH) therapy on thyroid function in children with GH deficiency (GHD). This study aimed to investigate longitudinal thyroid function changes over the first year of rGH therapy and assess the secretory capacity of the thyroid gland, using the Structure Parameter Inference Approach (SPINA-GT).

Methods: Prospective longitudinal cohort study in a single tertiary center.

Results: A total of 111 children with idiopathic GHD were treated with rGH (0.22 mg/kg/wk). Baseline median age was 10.0 years, with 84% being prepubertal. After 12 months of rGH therapy, IGF-1 levels significantly increased (P < .001), whereas free T4 (FT4) levels modestly declined (P = .008). Thyroid-stimulating hormone (TSH) and SPINA-GT index did not show significant changes. Mixed-effects modeling analysis revealed association of FT4 with IGF-1 SD score (P < .001), whereas TSH was not associated with any covariate.

Conclusion: The findings of our study are consistent with most previous studies, confirming that rGH therapy in children with GHD induces a modest, statistically significant decline in FT4 while maintaining stable TSH. FT4 was associated with the increase of IGF-1 SD score during rGH therapy while the addition of SPINA-GT evaluation supports the preservation of the thyroid secretory reserve during the first year of rGH treatment.

查看原文本刊更多论文

儿童和青少年特发性生长激素缺乏症在开始rGH治疗后的甲状腺功能。

目的：GH/ IGF-1与甲状腺轴相互关联。以前的研究报告了关于生长激素治疗对生长激素缺乏症儿童甲状腺功能影响的混合结果。本研究旨在利用结构参数推断法（SPINA-GT）研究rGH治疗第一年甲状腺功能的纵向变化，并评估甲状腺的分泌能力。方法：在单一三级中心进行前瞻性纵向队列研究。结果：111例特发性生长激素缺乏症患儿接受rGH治疗（0.22 mg/kg/周）。基线中位年龄为10.0岁，其中84%处于青春期前。经过12个月的rGH治疗后，IGF-1水平显著升高(pp结论：我们的研究结果与大多数先前的研究结果一致，证实了rGH治疗在GHD儿童中诱导FT4适度且具有统计学意义的下降，同时保持稳定的TSH。在rGH治疗期间，FT4与IGF-1 SDS的增加有关，而SPINA-GT评估的增加支持在rGH治疗的第一年保留甲状腺分泌储备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.